As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 clinical trial evaluating ...READ MORE ›
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.